ER
REGN icon

Enlightenment Research’s Regeneron Pharmaceuticals REGN Stock Holding History

Enlightenment Research’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-500
Closed -$344K – 72
2022
Q3 		$344K Buy
+500
New +$315K 0.76% 48
2021
Q4 		– Sell
-1,100
Closed -$666K – 186
2021
Q3 		$666K Buy
+1,100
New +$683K 0.81% 42

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Enlightenment Research's REGN Position: Q4 2022 in Review

Enlightenment Research sold out of Regeneron Pharmaceuticals (REGN) in Q4 2022, closing a stake of 500 shares — an estimated $344K sold.

Enlightenment Research first reported a position in REGN in Q3 2021 and held it in 2 quarters. The position peaked at $666K in Q3 2021. 1,160 funds tracked by Wall St. Rank hold REGN as of Q4 2022.

  • Enlightenment Research reported no remaining Regeneron Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Enlightenment Research sold 500 Regeneron Pharmaceuticals shares in Q4 2022, an estimated $344K.
  • Enlightenment Research first reported a position in Regeneron Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • Enlightenment Research's Regeneron Pharmaceuticals position peaked at $666K in Q3 2021.
  • 1,160 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2022.

Based on Enlightenment Research's 13F filing for Q4 2022.